Clinical trials: in Algeria
Growth Hormone Deficiency in Children
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
- Trial name
- REAL4 (NCT03811535)
- Testing
- Somapacitan, Norditropin®
- Where
- 139 sites in United States, Algeria and 24 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Stroke
Oral and Salivary Biomarkers Associated With Stroke
This observational study aims to investigate associations between oral and salivary biomarkers and stroke. Adults with stroke and healthy controls will undergo clinical oral assessment and unstimulated saliva collection.
- Trial name
- NCT07357155
- Where
- 2 sites in Algeria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital Center (CHU) of Constantine, Algeria
Short Stature Children Born Small for Gestational Age (SGA)
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already…
- Trial name
- NCT03878446
- Testing
- Somapacitan, Norditropin®
- Where
- 95 sites in United States, Algeria and 21 more
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Cerebellar Ataxias, Spastic Paraplegias
SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias
Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity.
- Trial name
- Spatax (NCT00140829)
- Where
- 27 sites in Algeria, Belgium and 13 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
- Trial name
- ENSURE-1 (NCT05134441)
- Testing
- IMU-838 tablets
- Where
- 103 sites in United States, Albania and 15 more
- Volunteers
- 1,121 people
- Sponsor
- Immunic AG
Haemophilia A and B With and Without Inhibitors
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
- Trial name
- Explorer10 (NCT05135559)
- Testing
- Concizumab
- Where
- 91 sites in United States, Algeria and 22 more
- Volunteers
- 153 people
- Sponsor
- Novo Nordisk A/S
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer8 (NCT04082429)
- Testing
- Concizumab
- Where
- 113 sites in United States, Algeria and 31 more
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer7 (NCT04083781)
- Testing
- Concizumab
- Where
- 99 sites in United States, Algeria and 27 more
- Volunteers
- 134 people
- Sponsor
- Novo Nordisk A/S
Obesity Difficult Airway Airway Management, Obesity Adult Onset
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
- Conditions
- Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Type 2 Diabetes Mellitus
- Trial name
- OBESIAL (NCT07779343)
- Testing
- Semaglutide (Wegovy) weekly injection, Behavioral Treatment, Weight loss
- Where
- Algeria
- Volunteers
- 300 people
- Sponsor
- University of Health Sciences, Algeria
Advanced Breast Cancer
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.
- Trial name
- VINOREAL (NCT06500494)
- Testing
- Vinorelbine Tartrate Oral
- Where
- 3 sites in Algeria, China and 1 more
- Volunteers
- 368 people
- Sponsor
- Pierre Fabre Medicament
End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria
Clinical Observation of Renal Function Reactivation Following a GRAS-Based Protocol in Patients With Chronic Kidney Disease and Long-Term Renal Arrest.
This observational study documents the impact of a specific oral protocol (based on FDA-GRAS ingredients) on patients with Stage 5 Chronic Kidney Disease (CKD).
- Conditions
- End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Stage 5
- Trial name
- NCT07555327
- Testing
- CSR-CKD Oral Protocol
- Where
- Algeria
- Volunteers
- 8 people
- Sponsor
- Amar h Zireg
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.
- Conditions
- Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI), Urinary Urgency
- Trial name
- AROMA-MS (NCT07599189)
- Testing
- Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil)
- Where
- 2 sites in Algeria
- Volunteers
- 60 people
- Sponsor
- University of Oran 1
Hereditary Angioedema (HAE)
A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals.
- Trial name
- AHAE (NCT07293364)
- Testing
- Technochrom C1-INH Kit
- Where
- Algeria
- Volunteers
- 514 people
- Sponsor
- Takeda
Osgood-Schlatter Disease
Combined Physical Therapy and Hold-Relax Technique for Adolescent Osgood-Schlatter Knee Pain
This pilot study evaluates the preliminary effectiveness of a combined rehabilitation program incorporating hold-relax (H-R) stretching techniques and progressive therapeutic exercises on knee pain and range of motion (ROM) in…
- Trial name
- NCT07590128
- Testing
- Hold-Relax Proprioceptive Neuromuscular Facilitation (PNF), Progressive Rehabilitation Program
- Where
- Algeria
- Volunteers
- 6 people
- Sponsor
- Benha University
Cardiac Arrhythmias, Symptoms and Signs
Confirm Rx Insertable Cardiac Monitor SMART Registry
The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period.
- Conditions
- Cardiac Arrhythmias, Symptoms and Signs, Atrial Fibrillation
- Trial name
- NCT03505801
- Testing
- Confirm Rx ICM insertion procedure
- Where
- 113 sites in United States, Algeria and 22 more
- Volunteers
- 1,826 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus, COVID-19
Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)
Diabetes is a major risk factor for severe COVID-19 and poor clinical outcomes during hospitalization. However, little is known about the medium- and long-term metabolic consequences of COVID-19 in people with diabetes after…
- Conditions
- Diabetes Mellitus, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- DMD-COV (NCT07560059)
- Testing
- No intervention (observational study)
- Where
- Algeria
- Volunteers
- 201 people
- Sponsor
- Algerian Society of Diabetology
Chronic Periodontitis, Chronic Periodontitis Wth Diabetes Mellitus
Metabolic Regeneration Registry for Periodontal Health (20-Patient Cohort).
This observational study documents the clinical outcomes of a proprietary, safe-to-swallow metabolic protocol for chronic gum disease.
- Conditions
- Chronic Periodontitis, Chronic Periodontitis Wth Diabetes Mellitus, Non-surgical Periodontal Treatment, Gingival Regeneration
- Trial name
- NCT07538661
- Testing
- Nutraceutical Bio-Active Oral Repair Formula (Food-Grade), Nutraceutical Bio-Active Oral Repair Formula
- Where
- Algeria
- Volunteers
- 20 people
- Sponsor
- Amar h Zireg
Breast Cancer, Her 2 Positive Breast Cancer
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings.
- Trial name
- PERTUREAL (NCT07542496)
- Where
- 2 sites in Algeria
- Volunteers
- 1,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Prostate Cancer, Prostate Cancer (Diagnosis)
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
- Trial name
- CLIQQC (NCT07484971)
- Where
- 24 sites in Algeria
- Volunteers
- 2,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Gastric Cancer, Gastric (Stomach) Cancer
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.
- Conditions
- Gastric Cancer, Gastric (Stomach) Cancer, Gastric Cancer (Diagnosis)
- Trial name
- ECLIPSE-CG (NCT07481110)
- Where
- 15 sites in Algeria
- Volunteers
- 1,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie